Going to look a bit deeper into this one..Similar scenario (albeit wildly different too) was TBR.Took a steep rise in price to trigger some selling, but then was well in the green.Homework time.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling